Bindu Kanapuru

7PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersData mining and knowledge discoveryMolecular medicineCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2026
Concordance Between Claims-Based and Electronic Health Record-Based Comorbidity Measures: An Application Using Linked Data.

|Mar 18, 2026
Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center-Medicare Database.

Tsung-Ying Lee, Eberechukwu Onukwugha, Abree Johnson

|Jun 04, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma, Xue Lin, Zhenzhen Xu

|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Andrea C Baines, Bindu Kanapuru, Jay Zhao

|May 07, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.

Kavita Natrajan, Megha Kaushal, Bindu George

|Dec 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco

Pageof 2

Frequent Collaborators

5 joint publications

Marc R Theoret

3 joint publications

Nicole J Gormley

2 joint publications

Andrea C Baines

2 joint publications

Donna Rivera